These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22273313)

  • 21. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
    Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose.
    Pandya DJ; Fitzsimmons BF; Wolfe TJ; Hussain SI; Lynch JR; Ortega-Gutierrez S; Zaidat OO
    J Neuroimaging; 2010 Jan; 20(1):64-9. PubMed ID: 19018951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
    von Beckerath N; Kastrati A; Wieczorek A; Pogatsa-Murray G; Sibbing D; Graf I; Schömig A
    Eur Heart J; 2007 Aug; 28(15):1814-9. PubMed ID: 17272357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
    Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
    Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
    Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to aspirin and clopidogrel monitored with different platelet function methods.
    Mani H; Linnemann B; Luxembourg B; Kirchmayr K; Lindhoff-Last E
    Platelets; 2006 Aug; 17(5):303-10. PubMed ID: 16928602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Price MJ; Nayak KR; Barker CM; Kandzari DE; Teirstein PS
    Am J Cardiol; 2009 May; 103(10):1339-43. PubMed ID: 19427425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention.
    van Werkum JW; van der Stelt CA; Seesing TH; Hackeng CM; ten Berg JM
    J Thromb Haemost; 2006 Nov; 4(11):2516-8. PubMed ID: 16938130
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
    Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalization of platelet reactivity in clopidogrel-treated subjects.
    Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
    J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
    Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
    Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2009 Nov; 124(5):588-91. PubMed ID: 19631365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
    Michelson AD; Linden MD; Furman MI; Li Y; Barnard MR; Fox ML; Lau WC; McLaughlin TJ; Frelinger AL
    J Thromb Haemost; 2007 Jan; 5(1):75-81. PubMed ID: 17002661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
    Lev EI; Arikan ME; Vaduganathan M; Alviar CL; Tellez A; Mathuria N; Builes A; Granada JF; del Conde I; Kleiman NS
    Am Heart J; 2007 Oct; 154(4):694.e1-7. PubMed ID: 17892993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.